Senti Bio
Vision
To outsmart the most complex diseases by programming logic into medicine with unprecedented efficacy, precision and control.
Approach
Senti Bio is a technology-driven therapeutics company focused on the next generation of medicine—where cells are the hardware and gene circuits are the software. Programming cells to respond, adapt and make decisions, Senti Bio is working to create smarter therapies with computer-like logic, enhanced functionality and greater control.
Senti Bio is applying its gene circuit technology platform to develop an internal proprietary pipeline of therapeutics that using allogeneic chimeric antigen receptor natural killer (CAR-NK) cells to address major challenges for people living with cancer. Gene circuits are novel and proprietary combinations of DNA that enable cells to sense their environment, perform logic and instruct cells to produce therapeutic proteins for enhanced efficacy, precision and control. Senti Bio believes that its approach to programming gene circuits in living cells may enable drug developers to build optimal functionality into almost any cell- or gene-based medicine.
Senti (SNTI) went public in December 2021.
CEO:
Tim Lu, MD, PhD
Founders:
Tim Lu, MD, PhD
Philip Lee, PhD
First investment:
October 2020